Healthcare Funds Stand Out for Portfolio Diversification Amid Technology Fluctuations
While fluctuations in technology stocks increase the need for portfolio diversification, healthcare funds offer strong returns and a balancing role thanks to developments in biotechnology and medical technologies.
While artificial intelligence and technology funds provided strong returns throughout the year, fluctuations in recent weeks have caused healthcare funds to stand out for the purpose of portfolio diversification. Developments in biotechnology and medical technologies—strengthened by Moderna and Merck's cancer vaccine studies—have bolstered the healthcare theme, and healthcare funds from various portfolio management companies have recently delivered positive returns.
Technology Fluctuations and the Healthcare Theme
Throughout much of the year, investments in artificial intelligence, chips, and technology, which stood out in foreign funds, provided strong returns. However, the fluctuations seen in technology stocks in recent weeks have once again demonstrated that tying an entire portfolio to a single narrative is risky.
At this point, healthcare funds are being closely monitored to balance the portfolio. Developments regarding Moderna and Merck's cancer vaccine studies, in particular, have brought the healthcare theme back to the forefront.
The Diversification Power of Healthcare Funds
Today, when we speak of healthcare, it is not just about traditional pharmaceutical companies; biotechnology, genetics, medical technologies, and AI-supported drug development processes are also becoming important parts of this theme.
According to assessments in The Wall Street Journal, major healthcare companies can move in the opposite direction of technology stocks. This makes healthcare funds not only a defensive tool, but a strong balancer for technology-weighted portfolios.
Recent Fund Returns
Looking at one-month performances, the movement in healthcare funds is clearly visible, and these funds are offering positive returns to their investors.
Hedef Portföy Healthcare Sector Variable Fund stood out with 13.87 percent, while Yapı Kredi Portföy Healthcare Sector Free Fund provided a return of 10.95 percent.
Differences in Fund Contents
Even if fund names are the same, their contents can differ from one another. Major companies such as Eli Lilly, Johnson & Johnson, AbbVie, UnitedHealth, Merck, AstraZeneca, Pfizer, Gilead, and Regeneron form the defensive backbone.
The real difference among funds arises depending on which growth-oriented areas—such as biotechnology, genetic technologies, or domestic healthcare companies—are added alongside this main backbone.
Risks Faced by the Sector
The healthcare sector does not only face positive developments; certain policies and regulations can also create pressure on the sector.
The Trump administration's pressure to drive down drug prices, its approach to Medicare spending, and statements regarding tariffs have been among the topics putting pressure on pharmaceutical companies during the year.
A Complement, Not an Alternative, to Technology
It offers a more accurate approach to view healthcare funds not as a direct alternative to technology, but as a complementary element to the portfolio alongside technology.
Benefiting from the growth story when technology is rising, and balancing the portfolio with more defensive areas like healthcare when technology fatigues, provides an advantage for investors.